GlassScriptPhysician profile
Louis B Gaudin
NPI 1144210618
$8,979.16
in general payments reported to CMS, 2019-2025
29 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $747 · 2021: $1,467 · 2022: $1,253 · 2023: $1,966 · 2024: $843 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,526 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,525.59 |
| Education | $199.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,648.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,378.60 | 2019-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,349.93 | 2019-2025 | Dupixent |
| Genzyme Corporation | $751.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $579.86 | 2019-2025 | |
| Pfizer INC. | $444.21 | 2019-2025 | |
| Csl Behring | $439.09 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $339.38 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $263.65 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $262.28 | 2019-2025 | |
| Amgen INC. | $215.72 | 2020-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.45 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $151.75 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $151.24 | 2020-2024 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $129.74 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $117.01 | 2019-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $112.15 | 2021-2025 | Ruconest |
| Alk-Abello, INC | $95.58 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $91.99 | 2023 | |
| Leo Pharma INC. | $65.45 | 2022-2025 | Anzupgo, Adbry |
| Organon LLC | $61.77 | 2025 | |
| Uswm, LLC | $35.00 | 2021 | |
| Aytu Biopharma, INC. | $33.14 | 2019-2025 | |
| Greer Laboratories, INC. | $24.79 | 2019 | |
| Grifols USA, LLC | $19.04 | 2022 | |
| Hikma Pharmaceuticals USA | $17.71 | 2023 | Ryaltris |
| Azurity Pharmaceuticals, INC. | $15.87 | 2025 | Alvesco |
| Phadia US INC. | $15.08 | 2022 | |
| Merck Sharp & Dohme LLC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Gaudin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.